Skip to main content
Year archive

Galapagos NV — 2014 filings

All 183 regulatory filings released by Galapagos NV (GLPG) in 2014, sourced directly from the official regulator.

183 Filings
2014 Period
2014 filings (183)
Filing Released Lang
Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie
Legal Proceedings Report
2014-12-19 English
Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie
Regulatory Filings
2014-12-19 English
Galapagos start Fase 1 studie in taaislijmziekte (mucoviscidose) en zal succesbetaling van AbbVie ontvangen
Regulatory Filings
2014-12-18 Dutch
Galapagos verkrijgt volledige rechten op GLPG1205
M&A Activity
2014-12-16 Dutch
Galapagos regains full rights to GPR84 inhibitor GLPG1205
Regulatory Filings
2014-12-16 English
Galapagos selects second component of its investigational cystic fibrosis combination treatment
Investor Presentation
2014-12-12 English
Galapagos selects second component of its investigational cystic fibrosis combination treatment
Regulatory Filings
2014-12-12 English
Galapagos selecteert GLPG2222 voor combinatie-medicijn tegen taaislijmziekte (CF)
Legal Proceedings Report
2014-12-11 Dutch
Galapagos increases share capital through warrant exercises
Share Issue/Capital Change
2014-12-10 English
Galapagos increases share capital through warrant exercises
Share Issue/Capital Change
2014-12-10 English
Share capital increase Q4 2014 NL_FINAL.pdf
Share Issue/Capital Change
2014-12-09 Dutch
Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA
Regulatory Filings
2014-11-24 English
Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA
Regulatory Filings
2014-11-24 English
Galapagos rondt werving van patiënten af voor DARWIN 2 monotherapie studie met GLPG0634 (filgotinib) in reuma
Legal Proceedings Report
2014-11-23 Dutch
Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014
Regulatory Filings
2014-11-17 English
Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014
Investor Presentation
2014-11-17 English
Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA
Regulatory Filings
2014-11-12 English
Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA
Earnings Release Q4 2014
2014-11-12 English
Galapagos completes recruitment for Darwin 1 study
Legal Proceedings Report
2014-11-12 English
Galapagos rondt werving van patiënten af voor Darwin 1 studie
Regulatory Filings
2014-11-12 Dutch
GSK discloses good efficacy in psoriasis with GSK2856184
Legal Proceedings Report
2014-11-06 English
GSK discloses good efficacy in psoriasis with GSK2856184
Regulatory Filings
2014-11-06 English
Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UK
Regulatory Filings
2014-10-27 English
Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UK
Regulatory Filings
2014-10-27 English
Galapagos and Calchan collaborate on osteoarthritis research,
Regulatory Filings
2014-10-27 English
Galapagos creates new warrant plan
Share Issue/Capital Change
2014-10-20 English
Galapagos creates new warrant plan
Share Issue/Capital Change
2014-10-20 English
Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week
Environmental & Social Information
2014-10-20 English
Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week
Regulatory Filings
2014-10-20 English
Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week
Earnings Release FY 2014
2014-10-20 English
Galapagos maakt nieuw target bekend en presenteert gunstige Fase 1 data van GLPG1205 tijdens UEG Week
Regulatory Filings
2014-10-20 Dutch
Bart Filius joins Galapagos as CFO
Board/Management Information
2014-10-15 English
Bart Filius joins Galapagos as CFO
Board/Management Information
2014-10-15 English
Bart Filius treedt toe als CFO van Galapagos
Board/Management Information
2014-10-15 Dutch
Galapagos presents novel cystic fibrosis combination therapy at NACFC
Investor Presentation
2014-10-09 English
Galapagos presents novel cystic fibrosis combination therapy at NACFC
Investor Presentation
2014-10-09 English
Galapagos presents novel cystic fibrosis combination therapy at NACFC
Regulatory Filings
2014-10-09 English
Galapagos presenteert nieuwe combinatie medicijnen voor taaislijmziekte op CF conferentie
Regulatory Filings
2014-10-09 Dutch
Galapagos increases share capital through warrant exercises
Share Issue/Capital Change
2014-09-26 English
Galapagos increases share capital through warrant exercises
Declaration of Voting Results & Voting Rights Announcements
2014-09-26 English
Share capital increase Q3 2014_FINAL.pdf
Share Issue/Capital Change
2014-09-25 English
Share capital increase Q3 2014 NL_FINAL.pdf
Share Issue/Capital Change
2014-09-25 Dutch
Galapagos reports high participation rate in long term extension study with GLPG0634 in RA patients
Earnings Release Q3 2014
2014-09-18 English
Galapagos reports high participation rate in long term extension study with GLPG0634 in RA patients
Earnings Release Q3 2014
2014-09-18 English
Galapagos cash position of €232 M provides solid basis for R&D pipeline investment
Earnings Release H1 2014
2014-08-08 English
Galapagos cash position of €232 M provides solid basis for R&D pipeline investment
Interim / Quarterly Report H1 2014
2014-08-08 English
Galapagos cash position of €232 M provides solid basis for R&D pipeline investment
Interim / Quarterly Report H1 2014
2014-08-08 English
Galapagos kaspositie van €232 miljoen vormt krachtig fundament onder investering in R&D pijplijn
Interim / Quarterly Report H1 2014
2014-08-08 Dutch
Interim Report 2014 FINAL.pdf
Interim / Quarterly Report H1 2014
2014-08-08 English
Halfjaarverslag 2014.pdf
Interim / Quarterly Report H1 2014
2014-08-08 Dutch
Galapagos receives milestone in osteoarthritis alliance with Servier
Regulatory Filings
2014-08-05 English
Galapagos receives milestone in osteoarthritis alliance with Servier
Regulatory Filings
2014-08-05 English
Galapagos receives milestone in osteoarthritis alliance with Servier
Regulatory Filings
2014-08-05 English
Galapagos ontvangt mijlpaalbetaling in artrose alliantie met Servier
Regulatory Filings
2014-08-05 Dutch
Galapagos creates new warrant plan
Share Issue/Capital Change
2014-07-28 English
Galapagos creates new warrant plan
Share Issue/Capital Change
2014-07-28 English
Galapagos creates new warrant plan
Remuneration Information
2014-07-25 English
Galapagos creëert nieuw warrantplan
Share Issue/Capital Change
2014-07-25 Dutch
MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development
Regulatory Filings
2014-07-23 English
MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development
Regulatory Filings
2014-07-23 English
MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development
Regulatory Filings
2014-07-23 English
Galapagos en MorphoSys brengen antilichaam tegen ontstekingsziekten in preklinische ontwikkeling
Regulatory Filings
2014-07-23 Dutch
Galapagos haalt €1,9 miljoen op door uitoefening van warrants
Share Issue/Capital Change
2014-07-07 Dutch
Galapagos haalt €1,9 miljoen op door uitoefening van warrants
Share Issue/Capital Change
2014-07-07 Dutch
Galapagos raises €1.9 million through warrant exercises
Share Issue/Capital Change
2014-07-04 English
Galapagos haalt €1,9 miljoen op door uitoefening van warrants
Share Issue/Capital Change
2014-07-04 Dutch
Galapagos initiates Phase 1 study with GLPG1690, triggering €6.6 M milestone in the alliance with Janssen Pharmaceutica NV
Legal Proceedings Report
2014-07-01 English
Galapagos initiates Phase 1 study with GLPG1690, triggering €6.6 M milestone in the alliance with Janssen Pharmaceutica NV
Regulatory Filings
2014-07-01 English
Galapagos start Fase 1 trial met GLPG1690 en ontvangt betaling van €6,6 miljoen in de alliantie met Janssen Pharmaceutica NV
Regulatory Filings
2014-07-01 English
Galapagos initiates Phase 1 study with GLPG1690, triggering €6.6 M milestone in the alliance with Janssen Pharmaceutica NV
Earnings Release H1 2014
2014-07-01 Dutch
Galapagos cystic fibrosis program progresses towards therapy for largest patient group
Investor Presentation
2014-06-17 English
Galapagos cystic fibrosis program progresses towards therapy for largest patient group
Regulatory Filings
2014-06-17 English
Galapagos cystic fibrosis program progresses towards therapy for largest patient group
Regulatory Filings
2014-06-17 English
Galapagos’ CF programma gaat richting medicijn voor grootste patiëntengroep
Regulatory Filings
2014-06-17 Dutch
Galapagos to hold Annual R&D Update on 17 June 2014 in New York
Report Publication Announcement
2014-05-13 English
Galapagos to hold Annual R&D Update on 17 June 2014 in New York
Report Publication Announcement
2014-05-13 English
Galapagos houdt jaarlijkse R&D Update op 17 juni 2014 in New York
Report Publication Announcement
2014-05-13 English
Galapagos houdt jaarlijkse R&D Update op 17 juni 2014 in New York
Report Publication Announcement
2014-05-13 Dutch
Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014
AGM Information
2014-05-01 English
Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014
AGM Information
2014-05-01 English
Galapagos announces management change
Board/Management Information
2014-04-28 English
Galapagos announces management change
Board/Management Information
2014-04-28 English
Galapagos announces management change
Board/Management Information
2014-04-28 English
Galapagos kondigt managementswijziging aan
Board/Management Information
2014-04-28 Dutch
Baker Brothers notify of 4.99% shareholding in Galapagos
Major Shareholding Notification
2014-04-25 English
Baker Brothers notify of 4.99% shareholding in Galapagos
Major Shareholding Notification
2014-04-25 English
trans notif_Baker_FINAL.pdf
Major Shareholding Notification
2014-04-24 English
trans notif_Baker_NL_FINAL.pdf
Director's Dealing
2014-04-24 Dutch
GSK2586184 met primary endpoint in Phase 2a psoriasis study
Regulatory Filings
2014-04-17 English
GSK2586184 met primary endpoint in Phase 2a psoriasis study
Regulatory Filings
2014-04-17 English
GSK2586184 met primary endpoint in Phase 2a psoriasis study
Regulatory Filings
2014-04-17 English
GSK2586184 toont werkzaamheid aan bij psoriasis patiënten in Fase 2a studie
Legal Proceedings Report
2014-04-17 Dutch
Galapagos haalt €2,4 miljoen op door uitoefening van warrants
Share Issue/Capital Change
2014-04-11 Dutch
Galapagos haalt €2,4 miljoen op door uitoefening van warrants
Share Issue/Capital Change
2014-04-11 Dutch
Share capital increase_10 April 2014_FINAL.pdf
Share Issue/Capital Change
2014-04-10 English
Share capital increase NL_10 april 2014_FINAL.pdf
Share Issue/Capital Change
2014-04-10 Dutch
Charles River Laboratories and Galapagos complete transaction
M&A Activity
2014-04-01 English
Charles River Laboratories and Galapagos complete transaction
M&A Activity
2014-04-01 English
Charles River Laboratories and Galapagos complete transaction
M&A Activity
2014-04-01 English
Charles River Laboratories en Galapagos ronden transactie af
Capital/Financing Update
2014-04-01 Dutch
Invitation to the Annual and Extraordinary General Shareholders' Meetings to be held on 29 April 2014
AGM Information
2014-03-31 English
Invitation to the Annual and Extraordinary General Shareholders' Meetings to be held on 29 April 2014
AGM Information
2014-03-31 English
EGM_NL_FINAL.pdf
AGM Information
2014-03-28 Dutch
140328_AGM-EGM_140429_Attendance Notification Form.pdf
AGM Information
2014-03-28 Dutch
140328_AGM EGM 140429_Proxy Forms.pdf
AGM Information
2014-03-28 Dutch
140328_Auditor Report on the non-consolidated accounts 2013_E.pdf
Audit Report / Information FY 2013
2014-03-28 English
140328_AGM 140429_Shares and Voting Rights.pdf
Share Issue/Capital Change
2014-03-28 Dutch
140328_BoD Report - 604 - Authorized Capital - E (Website).pdf
Capital/Financing Update
2014-03-28 English
140328_BoD Report - 604 - Authorized Capital - D (Website).pdf
Capital/Financing Update
2014-03-28 Dutch
140328_AGM 140328_Attendance Formalities_E.pdf
AGM Information
2014-03-28 English
140328_Auditor Report on the non-consolidated accounts 2013_D.pdf
Audit Report / Information FY 2013
2014-03-28 Dutch
140328_AGM 29 April 2014 - Convening Notice - E.pdf
AGM Information
2014-03-28 English
140328_AGM 140429_Attendance Formalities_D.pdf
AGM Information
2014-03-28 Dutch
EGM_FINAL.pdf
AGM Information
2014-03-28 English
140328_AGM 29 April 2014 - Convening Notice - D.pdf
AGM Information
2014-03-28 Dutch
AGM_FINAL.pdf
AGM Information
2014-03-28 English
AGM_NL_FINAL.pdf
AGM Information
2014-03-28 Dutch
Galapagos_Annual Report_EN_2013.pdf
Annual Report FY 2013
2014-03-28 English
Galapagos_Annual Report_NL_2013.pdf
Annual Report FY 2013
2014-03-28 Dutch
140328_BoD Report - 604 - Authorized Capital - E (Website).pdf
Capital/Financing Update
2014-03-28 Dutch
140328_Galapagos NV - Statutaire Jaarrekening 31-12-2013.pdf
Annual Report FY 2013
2014-03-28 Dutch
140328_AGM-EGM_140429_Attendance Notification Form.pdf
AGM Information
2014-03-28 Dutch
140328_AGM EGM 140429_Proxy Forms.pdf
AGM Information
2014-03-28 Dutch
140328_AGM 140429_Shares and Voting Rights.pdf
Share Issue/Capital Change
2014-03-28 Dutch
140328_BoD Report - 604 - Authorized Capital - D (Website).pdf
Capital/Financing Update
2014-03-28 Dutch
140328_Auditor Report on the non-consolidated accounts 2013_E.pdf
Audit Report / Information FY 2013
2014-03-28 English
140328_Auditor Report on the non-consolidated accounts 2013_D.pdf
Audit Report / Information FY 2013
2014-03-28 Dutch
140328_AGM 140328_Attendance Formalities_E.pdf
AGM Information
2014-03-28 English
140328_AGM 29 April 2014 - Convening Notice - D.pdf
AGM Information
2014-03-28 Dutch
140328_AGM 29 April 2014 - Convening Notice - E.pdf
AGM Information
2014-03-28 English
140328_AGM 140429_Attendance Formalities_D.pdf
AGM Information
2014-03-28 Dutch
AGM_FINAL.pdf
AGM Information
2014-03-28 English
AGM_NL_FINAL.pdf
AGM Information
2014-03-28 Dutch
Euronext Amsterdam to become Market of Reference for Galapagos
Regulatory Filings
2014-03-21 English
Euronext Amsterdam to become Market of Reference for Galapagos
Regulatory Filings
2014-03-21 English
Euronext Amsterdam to become Market of Reference for Galapagos
Regulatory Filings
2014-03-21 English
Euronext Amsterdam wordt referentiemarkt voor Galapagos
Delisting Announcement
2014-03-21 Dutch
Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego
Regulatory Filings
2014-03-18 English
Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego
Investor Presentation
2014-03-18 English
Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego
Investor Presentation
2014-03-18 English
Galapagos presenteert goede preklinische data van GLPG1790, een selectieve remmer van ephrin receptor kinase, op AACR in San Diego
Regulatory Filings
2014-03-18 Dutch
Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to €134 million
M&A Activity
2014-03-13 English
Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to €134 million
M&A Activity
2014-03-13 English
Charles River Laboratories to acquire Galapagos’ Argenta and BioFocus service operations for up to €134 million
M&A Activity
2014-03-13 English
Charles River Laboratories koopt Galapagos’ Argenta en BioFocus service activiteiten voor €134 miljoen
M&A Activity
2014-03-13 Dutch
FY2013_FINAL.pdf
Earnings Release FY 2013
2014-03-07 English
FY2013_NL_final.pdf
Earnings Release FY 2013
2014-03-07 Dutch
Galapagos reports 2013 financial results
Earnings Release FY 2013
2014-03-07 English
Galapagos reports 2013 financial results
Earnings Release FY 2013
2014-03-07 English
Galapagos receives €2 million from osteoarthritis alliance with Servier
Regulatory Filings
2014-03-07 English
Galapagos receives €2 million from osteoarthritis alliance with Servier
M&A Activity
2014-03-07 English
Galapagos receives €2 million from osteoarthritis alliance with Servier
Regulatory Filings
2014-03-07 English
Galapagos ontvangt €2 miljoen in artrose alliantie met Servier
M&A Activity
2014-03-07 Dutch
Galapagos provides status update for GSK2586184 in GSK’s psoriasis, lupus, and ulcerative colitis clinical studies
Regulatory Filings
2014-02-28 English
Galapagos provides status update for GSK2586184 in GSK’s psoriasis, lupus, and ulcerative colitis clinical studies
Regulatory Filings
2014-02-28 English
Galapagos provides status update for GSK2586184 in GSK’s psoriasis, lupus, and ulcerative colitis clinical studies
Regulatory Filings
2014-02-28 English
Galapagos geeft een update van de status van GSK2586184 in GSK’s psoriasis- , lupus- en colitis ulcerosa patiënten-studies
Regulatory Filings
2014-02-28 Dutch
Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD
Investor Presentation
2014-02-21 English
Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD
Regulatory Filings
2014-02-21 English
Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD
Investor Presentation
2014-02-21 English
Galapagos presenteert GLPG0634 en GLPG0974 op internationaal IBD-congres
Regulatory Filings
2014-02-21 Dutch
Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative colitis
Regulatory Filings
2014-02-17 English
Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative colitis
Regulatory Filings
2014-02-17 English
Galapagos completes patient recruitment in Proof of Concept
Regulatory Filings
2014-02-17 English
Galapagos rondt werving van patiënten af voor de Fase 2 klinische studie met GLPG0974 in colitis ulcerosa
Regulatory Filings
2014-02-17 Dutch
Galapagos receives €2.3 million IWT grant for fibrosis research
Regulatory Filings
2014-02-03 English
Galapagos receives €2.3 million IWT grant for fibrosis research
Capital/Financing Update
2014-02-03 English
Galapagos receives €2.3 million IWT grant for fibrosis research
Regulatory Filings
2014-02-03 English
Galapagos ontvangt €2,3 miljoen subsidie voor onderzoek naar fibrose
Capital/Financing Update
2014-02-03 Dutch
First clinical centers opened for Phase 2 Crohn's study with GLPG0634
Regulatory Filings
2014-01-29 English
First clinical centers opened for Phase 2 Crohn's study with GLPG0634
Investor Presentation
2014-01-29 English
First clinical centers opened for Phase 2 Crohn’s study with GLPG0634
Regulatory Filings
2014-01-29 English
Galapagos start klinische Fase 2 met GLPG0634 in ziekte van Crohn
Legal Proceedings Report
2014-01-29 Dutch
Galapagos selects pre-clinical candidate for cystic fibrosis
Regulatory Filings
2014-01-16 English
Nieuw kandidaat medicijn tegen taaislijmziekte
Regulatory Filings
2014-01-16 Dutch
Galapagos receives €2.9 million IWT grant for cystic fibrosis research
Regulatory Filings
2014-01-13 English
Galapagos receives €2.9 million IWT grant for cystic fibrosis research
Regulatory Filings
2014-01-13 English
Galapagos receives €2.9 million IWT grant for cystic fibrosis research
Regulatory Filings
2014-01-13 English
Galapagos ontvangt €2,9 miljoen subsidie voor onderzoek naar taaislijmziekte
Regulatory Filings
2014-01-13 Dutch
Van Herk Investments notify of 5.3% shareholding in Galapagos
Major Shareholding Notification
2014-01-07 English
Van Herk Investments notify of 5.3% shareholding in Galapagos
Major Shareholding Notification
2014-01-07 English
140106 trans notif_Van Herk_FINAL.pdf
Major Shareholding Notification
2014-01-06 English
140106 trans notif_Van Herk_NL_FINAL.pdf
Major Shareholding Notification
2014-01-06 Dutch